
Please try another search
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.
Name | Age | Since | Title |
---|---|---|---|
Vuk Jemeric | - | 2023 | Director |
Simon Tarsh | 63 | 2022 | Independent Director |
Ajit Singh | 60 | 2024 | Independent Director |
Timothy R. Ramdeen | 33 | 2023 | Independent Non-Executive Director |
Sunetra Gupta | - | - | Member of Scientific Advisory Board |
Andrew J. Oakley | 63 | 2025 | Chairman |
Thomas Meier | 63 | 2024 | Independent Director |
John Mccune Rice | 75 | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review